Study S000086

A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction

ClinicalTrials.gov record

Registration

Registration: NCT06313528
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 85
Start: 2024-03-20
Primary completion: 2025-08-26
Lead sponsor: Eli Lilly and Company
Conditions: Obesity
Interventions: DRUG:LY3437943; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J1I-MC-GZBW

Registered primary outcomes

Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined) [Baseline up to Week 17 (inclusive)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.